TULARIK Trademark

Trademark Overview

On Wednesday, October 13, 2004, a trademark application was filed for TULARIK with the United States Patent and Trademark Office. The USPTO has given the TULARIK trademark a serial number of 78499007. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 11, 2009. This trademark is owned by Amgen Inc.. The TULARIK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the treatment of diseases and disorders associated with endocrinology, immune response, inflammation, nephrology, neurology, oncology, urology, metabolism and genetics, and complications associated therewith
tularik

General Information

Serial Number78499007
Word MarkTULARIK
Filing DateWednesday, October 13, 2004
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 11, 2009
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 17, 2006

Trademark Statements

Goods and ServicesPharmaceutical preparations for use in the treatment of diseases and disorders associated with endocrinology, immune response, inflammation, nephrology, neurology, oncology, urology, metabolism and genetics, and complications associated therewith

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 20, 2004
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799
Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201789

Trademark Events

Event DateEvent Description
Monday, May 11, 2009ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, May 11, 2009ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 30, 2008EXTENSION 5 GRANTED
Monday, September 29, 2008EXTENSION 5 FILED
Tuesday, September 30, 2008CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, September 29, 2008TEAS EXTENSION RECEIVED
Monday, April 14, 2008EXTENSION 4 GRANTED
Monday, March 31, 2008EXTENSION 4 FILED
Monday, March 31, 2008TEAS EXTENSION RECEIVED
Thursday, October 11, 2007ASSIGNED TO EXAMINER
Monday, September 24, 2007EXTENSION 3 GRANTED
Tuesday, September 11, 2007EXTENSION 3 FILED
Tuesday, September 11, 2007TEAS EXTENSION RECEIVED
Tuesday, July 17, 2007EXTENSION 2 GRANTED
Monday, April 2, 2007EXTENSION 2 FILED
Monday, April 2, 2007TEAS EXTENSION RECEIVED
Wednesday, November 29, 2006EXTENSION 1 GRANTED
Tuesday, October 10, 2006EXTENSION 1 FILED
Tuesday, October 10, 2006TEAS EXTENSION RECEIVED
Tuesday, September 26, 2006TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 11, 2006NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 17, 2006PUBLISHED FOR OPPOSITION
Wednesday, December 28, 2005NOTICE OF PUBLICATION
Wednesday, December 7, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, November 8, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 8, 2005EXAMINER'S AMENDMENT ENTERED
Monday, November 7, 2005ASSIGNED TO LIE
Thursday, November 3, 2005EXAMINERS AMENDMENT E-MAILED
Thursday, November 3, 2005EXAMINERS AMENDMENT -WRITTEN
Tuesday, May 17, 2005NON-FINAL ACTION E-MAILED
Tuesday, May 17, 2005NON-FINAL ACTION WRITTEN
Monday, May 16, 2005ASSIGNED TO EXAMINER
Wednesday, October 20, 2004NEW APPLICATION ENTERED IN TRAM

Related Keywords

tularik associated urology neurology oncology metabolism therewith complications genetics nephrology response